



UNITED STATES PATENT AND TRADEMARK OFFICE

chy
UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/625,969	07/23/2003	Brent A. Johnson	17592 (AP)	1610

51957 7590 11/30/2006

ALLERGAN, INC.
2525 DUPONT DRIVE, T2-7H
IRVINE, CA 92612-1599

EXAMINER

SOROUGH, LAYLA

ART UNIT	PAPER NUMBER
----------	--------------

1617

DATE MAILED: 11/30/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 10/625,969	Applicant(s) JOHNSON, BRENT A.	
	Examiner Layla Soroush	Art Unit 1617	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 06 September 2006.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-17 and 23-37 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-17 and 23-37 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

The response filed September 6, 2006 presents remarks and arguments submitted to the office action mailed June 6, 2006 is acknowledged.

Applicant's election of Group I claims 1-18 and 28-37 with traverse is herein acknowledged.

The traversal is on the ground(s) that the inventions are closely related, and does not place an undue burden on Examiner is not persuasive.

In response, Examiner respectfully reiterates the restriction is proper when the inventions are shown to be distinct: For example, "Inventions II and I are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make another and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case another materially different product, e.g. a dentifrice composition, can be made using the method herein." Therefore, Applicant's argument is not found persuasive.

Notice of Possible Rejoinder

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. **Process claims that depend from or otherwise include all the limitations of the patentable product** will be entered as a

matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai*, *In re Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder.** Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

The requirement is still deemed proper and is therefore made **FINAL**.

Art Unit: 1617

Applicant's amendments submitted September 6, 2006 is acknowledged wherein claims 198-27 and 38 are withdrawn.

Applicant's arguments over the 35 U.S.C. 103 (a) rejection of claims 1-4, 6-18, 28-32, 36 and 37 over Sefton (US Pat. No. 6,262,117 B1) in view of Shefer et al. (US Pat. No.6,825,161 B2), and further in view of Hawley's Condensed Chemical Dictionary is not persuasive. Therefore, the rejection is maintained for the reasons of record.

The Applicant presented no arguments over the 35 U.S.C. 103 (a) rejection of claim 33 over Sefton (US Pat. No. 6,262,117 B1) in view of Shefer et al. (US Pat. No.6,825,161 B2) and Hawley's Condensed Chemical Dictionary and further in view of Johnson (US Pat. No. 6,414,032 B1). Therefore, the rejection is maintained for the reasons of record.

The Applicant presented no arguments over the 35 U.S.C. 103 (a) rejection of claims 5, 34, and 35 over Sefton (US Pat. No. 6,262,117 B1) in view of Shefer et al. (US Pat. No.6,825,161 B2) and Hawley's Condensed Chemical Dictionary and further in view of Maibach et al. (Pub No. US2003/0077301 A1). Therefore, the rejection is maintained for the reasons of record.

The rejection is restated below for applicant's convenience.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the

Art Unit: 1617

invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-4, 6-17, 28-32, 36 and 37 are rejected under 35 U.S.C. 103(a) as being unpatentable over Sefton (US Pat. No. 6,262,117 B1) in view of Shefer et al. (US Pat. No. 6,825,161 B2), and further in view of Hawley's Condensed Chemical Dictionary.

Sefton teaches serially applying azelaic acid (carboxylic acid) and benzoyl peroxide (peroxide) topical compositions for treatment of acne. Additionally, the benzoyl peroxide is more preferably used as a hydrous (water containing) benzoyl peroxide and is preferably suspended in the form of microparticles (solid particles) (column 2, lines 33-35), recited in claims 1, 2, 4, 6, and 16. Though water is not explicitly taught by the reference, compositions in hydrous form contain water and therefore, claim 28 is rendered obvious by the reference. The prior art teaches the anti-acne composition in the absence of retinoids (column 8, lines 24-27 -- claim 1), as recited in claim 36.

The reference teaches the combination of azelaic acid and benzoyl peroxide in a single topical composition provides ease of application (column 7, lines 50-53 and column 8, lines 24-27).

However, in the Background of the Art, Sefton teaches benzoyl peroxide has an inherent problem of decomposing coingredients in topical formulations to thereby cause itching upon application (column 1, lines 58-60). Additionally, the reference teaches benzoyl peroxide suspended in the form of microparticles (solid particles), (column 2, lines 33-35) but the reference fails to teach a composition comprising both benzoyl

Art Unit: 1617

peroxide suspended in the form of microparticles (solid particles) and a carboxylic acid.

Also, the reference fails to teach the size of the microspheres.

Shefer et al. teaches a method of controlling the release rate of an active agent, as well as fragrances in soap bar products and soap compositions (topical agents) (column 6, lines 1-3). The active agents are incorporated into nanosphere matrices (solid particles), that are encapsulated in moisture sensitive microspheres (solid particles) (see abstract). Components incorporated in the matrices (solid particles) are cosmetic, dermatological, or pharmaceutical active agents. Further, the prior art teaches active agents include anti-acne actives such as salicylic acid, benzoyl peroxide, and azelaic acid (column 17, lines 1-10). The reference teaches the material forming the nanosphere (solid particles) are "inert nontoxic hydrophobic materials with a melting point between about 20 degrees C and about 90 degrees C," recited in claims 10-14, and 37. Examples of hydrophobic materials (solid particles) include animal waxes such as beeswax (column 13, lines 4-10), recited in claim 9. The reference, teaches in Example 2, jojoba oil as a component of the controlled release system (see column 26, lines 64-67). The jojoba oil is encapsulated in the hydrophobic nanosphere and a powder floral fragrance is encapsulated in the microsphere (see column 26, lines 20-25), as recited in claim 17.

It would have been obvious to a person of ordinary skill in the art at the time of the invention was made to modify the teaching of Sefton by incorporating one active agent in the solid particles because Sefton teaches suspension of an active agent in microparticles (solid particles) is preferable and also, the reference teaches benzoyl

Art Unit: 1617

peroxide has an inherent problem of decomposing coingredients in topical formulations to thereby cause itching upon application. The motivation to make the incorporation is found in the Shefer et al. reference because it teaches the matrix material provide good barrier properties, low toxicity and irritancy, stability, and high loading capacity for the active agents (column 3, lines 11-15). Therefore, the skilled artisan would have had a reasonable expectation of successfully producing a composition with good barrier properties, low toxicity and irritancy, stability, and high loading capacity for the anti-acne active agents.

Additionally, it would have been obvious to a person of ordinary skill in the art at the time of the invention was made to modify the teaching of Sefton by incorporating specific solid particles because Sefton teaches suspension in the form of microparticles (solid particles) is preferable but fails to teach specific types of solid particles. The motivation to incorporate the specific microparticles (solid particles) is found in the Shefer et al. reference because it teaches beeswax as a suitable solid core material and the matrix material provide good barrier properties, low toxicity and irritancy, stability, and high loading capacity for the active agents (column 3, lines 11-15). Therefore, the skilled artisan would have had a reasonable expectation of successfully producing a composition with good barrier properties, low toxicity and irritancy, stability, and high loading capacity for the anti-acne active agents using the said solid particles.

Shefer et al teaches the size of the nanospheres of the claimed invention but fails to teach the size of the microspheres that encapsulate the nanospheres. However, by definition microspheres are in the micron size range (20–150 μ) or (0.02mm to 0.15

Art Unit: 1617

mm), and therefore meet the instant claims 7, 8, and 18 (See attached copy, Hawley's Condensed Chemical Dictionary).

The limitation "wherein said composition is useful for treating acne," in claim 1, is an intended use and receives no patentable weight in the composition claim.

The limitation "a package is suitable for dispensing the therapeutically active agents" recited in claim 28 does not further limit the composition. The container for storage of the pharmaceutical composition is immaterial to the claimed invention and therefore receives no patentable weight in a composition claim. Additionally, limitations of the package recited in claims 29-32 receive no patentable weight.

Claim 33 is rejected under 35 U.S.C. 103(a) as being unpatentable over Sefton (US Pat. No. 6,262,117 B1) in view of Shefer et al. (US Pat. No. 6,825,161 B2) and Hawley's Condensed Chemical Dictionary, as applied to claims 1-4, 6-17, 28-32, 36 and 37 above, and further in view of Johnson (US Pat. No. 6,414,032 B1).

Sefton, Shefer et al., and Hawley's Condensed Chemical Dictionary are as discussed above.

Sefton teaches humectants such as glycerin, propylene glycol, polyethylene glycol.

Sefton does not expressively teach the said humectants as viscosity enhancing agents.

Johnson teaches polyethylene glycols and polypropylene glycols as components in an antiseptic composition suitable for topical administration to the skin. The reference teaches the ingredients are widely used in order to increase viscosity or to

Art Unit: 1617

increase the tackiness of a composition. Therefore, it would have been obvious to a person of ordinary skill in the art at the time the invention was made to employ the humectants of Sefton's invention with the expectation of producing a viscous enhanced composition.

Claims 5, 34, and 35 are rejected under 35 U.S.C. 103(a) as being unpatentable over Sefton (US Pat. No. 6,262,117 B1) in view of Shefer et al. (US Pat. No. 6,825,161 B2) and Hawley's Condensed Chemical Dictionary, as applied to claims 1-4, 6-17, 28-32, 36 and 37 above, and further in view of Maibach et al. (Pub No. US2003/0077301 A1).

Sefton, Shefer et al., and Hawley's Condensed Chemical Dictionary are as discussed above.

Sefton and Shefer et al. do not specifically teach hydrogen peroxide, or tazarotene as components in the composition.

Maibach et al. teaches topical agents employed to treat acne include hydrogen peroxide, retinoids such as tazarotene, antibiotic such as azelaic acid (page 1, paragraph [0010], lines 1-19).

Thus Maibach teaches the equivalence of the various agents used for treating acne. Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to modify the Sefton composition by substituting the benzoyl peroxide with hydrogen peroxide, and employing tazarotene, as an ethyl ester of a carboxylic acid. The motivation to make such a substitution is because benzoyl peroxide, hydrogen peroxide, and tazarotene are all active agents employed for making

compositions to treat acne and substituting one active agent with another is with the expectation of similar efficacy in the treatment of acne.

Response to Arguments

Applicant's arguments filed September 6, 2006 have been fully considered but they are not persuasive for the reasons set forth below.

Applicant argues that the teaching of Sefton that "benzoyl peroxide has inherent problem of decomposing coingredients in topical formulations to thereby cause itching upon application" is part of the background and was initially described in Bouillon (US Pat. No. 4,691,956). Further, applicant explains that Bouillon teaches "that some carboxylic acid esters stabilize benzoyl peroxide, and because Bouillon does not teach the combination of azelaic acid and benzoyl peroxide, a person of ordinary skill in the art would know that Sefton's mention of "decomposing coingredients" does not refer to instability problems between azelaic acid and benzoyl peroxide. Sefton does not mention a problem of instability between benzoyl peroxide and azelaic acid. Thus, Sefton would not suggest to a person of ordinary skill that the combination of benzoyl peroxide and azelaic acid would have stability problems."

Additionally, the applicant argues that there is no incentive to further modify the composition of Sefton in the form of microparticles.

Response to Applicant's arguments: In the Background of Sefton and the Bouillon reference, the instability of benzoyl peroxide is taught.. The Examiner cited the teachings in the Background of Sefton solely to show that "benzoyl peroxide has inherent problem of decomposing coingredients in topical formulations to thereby cause

Art Unit: 1617

itching upon application.” Therefore, the prior art teaches benzoyl peroxide is unstable, per se, and that there are different methods of stabilizing the compound such as that taught in Bouillion.

Examiner reiterates that the sole purpose of citing the teachings in the Background of Sefton is to show that it is well known in the prior art that “benzoyl peroxide has inherent problem of decomposing coingredients in topical formulations to thereby cause itching upon application.” Sefton also teaches benzoyl peroxide suspended in the form of microparticles (solid particles), (column 2, lines 33-35). The Shefer reference was incorporated to show that the matrix material provide good barrier properties, low toxicity and irritancy, stability, and high loading capacity for the active agents (column 3, lines 11-15). Therefore, nanospheres (solid particles) of the prior art are known to provide stability to various compounds. Shefer et al. teaches compounds such as benzoyl peroxide can be incorporated into the nanospheres. Therefore, the combination of both teachings provides motivation to incorporate the benzoyl peroxide into nanosphere (solid particles) claimed by the Applicant.

The arguments are not persuasive and the rejection is made **FINAL**.

THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the

Art Unit: 1617

shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.


Conclusion

No claims allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Layla Soroush whose telephone number is (571)272-5008. The examiner can normally be reached on Monday through Friday from 8:30 a.m. to 5:00 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan, can be reached on (571) 272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



SREENI PADMANABHAN
SUPERVISORY PATENT EXAMINER